Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model.

Abstract

Bone-seeking radiopharmaceuticals such as ethylenediaminetetramethylene phosphonate (EDTMP) complexes of samarium-153 and holmium-166 are receiving considerable attention for therapeutic treatment of bone metastases. In this study, using the baboon experimental model, multicompartmental analysis revealed that with regard to pharmacokinetics, biodistribution, and skeletal localisation, 166Ho-EDTMP was significantly inferior to 153Sm-EDTMP and 99mTc-MDP. A more suitable 166Ho-bone-seeking agent should thus be sought for closer similarity to 153Sm-EDTMP to exploit fully the therapeutic potential of its shorter half-life and more energetic beta radiation.

• Authors: W K Louw, I C Dormehl, A J van Rensburg, N Hugo, A S Alberts, O E Forsyth, G Beverley, M A Sweetlove, J Marais, M G Lötter, A van Aswegen
• Journal: Nuclear medicine and biology (Nucl Med Biol) Vol. 23 Issue 8 Pg. 935-40 (Nov 1996) ISSN: 0969-8051 [Print] United States
• PMID: 9004281 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Organometallic Compounds
• Organophosphorus Compounds
• Radioisotopes
• Radiopharmaceuticals
• holmium ethylenediaminetetramethylenephosphonate
• Samarium
• samarium Sm-153 lexidronam
• Holmium

Topics

• Absorption
• Animals
• Body Fluid Compartments
• Bone and Bones (metabolism)
• Evaluation Studies as Topic
• Half-Life
• Holmium (pharmacokinetics)
• Male
• Organometallic Compounds (pharmacokinetics)
• Organophosphorus Compounds (pharmacokinetics)
• Papio
• Radioisotopes (pharmacokinetics)
• Radiopharmaceuticals (pharmacokinetics)
• Samarium (pharmacokinetics)
• Tissue Distribution